Q-omics provides the consensus-scored PPM1J profile across patient tissues and cancer cell-line models. PPM1J expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PPM1J is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PPM1J RNA expression shows 16,627 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where PPM1J shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPM1J — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPM1J survival associations across molecular data types. PPM1J RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPM1J RNA expression–survival associations across cancer types. High PPM1J expression shows unfavorable associations in KIRC, ACC and LGG, but favorable associations in STAD, CESC and THCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for PPM1J RNA expression.
This table summarizes PPM1J tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PPM1J. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPM1J shows lower tumor expression in KIRC and higher tumor expression in COAD, LUAD, LUSC, BRCA and BLCA. The KIRC box plot shows higher PPM1J RNA expression in normal versus tumor tissue (log2 FC = −0.978, t-test p < 0.001).
This table shows molecular features associated with PPM1J in patient tissues and cancer cell lines. In patient samples, PPM1J shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PPM1J RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in CNS and SOFT_TISSUE.
